Mobile App for Nephrotic Syndrome Management
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a mobile app called UrApp, designed to help families manage nephrotic syndrome, a kidney condition often affecting children. The researchers aim to determine if UrApp can improve disease management and the health of the children involved. Participants will either use the app or continue their usual care routine (standard of care) for one year. The trial seeks caregivers of children diagnosed with steroid-sensitive nephrotic syndrome in the last six weeks who have internet access at home. As an unphased trial, it offers families the chance to contribute to innovative research that could enhance disease management.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What prior data suggests that the UrApp is safe for nephrotic syndrome management?
Research shows that UrApp is a mobile app designed to help families manage childhood nephrotic syndrome. The app tracks urine tests and medication, aiming to improve home management of the condition. As a digital tool, UrApp doesn't carry the same safety concerns as medications. Sources report no negative effects from its use. It primarily serves as a learning and monitoring tool, indicating that users generally find it easy to use.
The sources do not reveal any specific safety issues with UrApp, suggesting it is likely safe for families managing nephrotic syndrome. However, participants should follow study guidelines and report any problems they encounter.12345Why are researchers excited about this trial?
Researchers are excited about the UrApp because it offers a unique approach to managing nephrotic syndrome by integrating digital health technology with the standard of care. Unlike traditional treatment options, which typically involve medication and regular doctor visits, UrApp provides patients with a mobile app designed to help them track their symptoms and manage their condition more effectively at home. This innovative tool aims to enhance patient engagement and empower individuals to take a proactive role in their health management, potentially leading to better outcomes and improved quality of life.
What evidence suggests that UrApp is effective for nephrotic syndrome management?
Studies have shown that the UrApp mobile application holds promise for helping families manage childhood nephrotic syndrome. Research indicates that this app can track urine tests and medication more effectively. Early results from a small study suggested that the app improved how families monitor and manage the condition. In this trial, participants in one arm will use the UrApp mobile application alongside the standard of care. This is important because better management can lead to fewer relapses and complications. The app aims to simplify following the treatment plan, potentially improving children's health outcomes.12367
Who Is on the Research Team?
Chia-shi Wang, MD, MS
Principal Investigator
Emory University
Are You a Good Fit for This Trial?
This trial is for caregivers of children aged 1-17 newly diagnosed with steroid-sensitive nephrotic syndrome, a chronic kidney disease. Participants must have internet access, be proficient in English, and the child should respond to steroids within 4 weeks. It's not for those caring for kids who've had a kidney transplant or have secondary causes like lupus.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to either the UrApp or standard of care and followed for one year
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Standard of Care
- UrApp
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator